CliffBio
biologic

Blenrep

belantamab mafodotin-blmf

Loss of exclusivityOctober 2037projected — 12-year biologic exclusivity estimate
CompanyGlaxoSmithKline →See this company's full patent-cliff portfolio

Drug detail

Brand nameBlenrep
Active ingredientbelantamab mafodotin-blmf
Strength70MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalOctober 2025
Marketing statusRx

More from GlaxoSmithKline

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.